Edgewise Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Edgewise Therapeutics (EWTX).

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

9Buy

3Hold

Consensus RatingOutperform# Analysts12Avg. Consensus PT$46Upside to Avg. PT+8.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 20, 2026	JP Morgan	Tessa Romero	PT Raise	Overweight	$53→$60
Aug 11, 2026	Goldman Sachs	Paul Choi	PT Raise	Neutral	$32→$36
Jul 20, 2026	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$45→$55
Jul 9, 2026	Oppenheimer	Mazahir Alimohamed	Initiate	Outperform	$51
Jul 6, 2026	Guggenheim	Debjit Chattopadhyay	PT Raise	Buy	$41→$51
Jun 17, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$48→$59
Jun 17, 2026	Goldman Sachs	Paul Choi	PT Raise	Neutral	$20→$32
Jun 16, 2026	HC Wainwright & Co.	Lander Egaña Gorroño	Maintained	Buy	$45
Jun 2, 2026	HC Wainwright & Co.	Lander Egaña Gorroño	PT Raise	Buy	$42→$45
Jun 2, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$50→$48
Jun 2, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$46→$52
Mar 17, 2026	JP Morgan	Tessa Romero	PT Raise	Overweight	$34→$45
Mar 17, 2026	Wedbush	Laura Chico	Maintained	Outperform	$32
Feb 27, 2026	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$30→$45
Nov 14, 2025	JP Morgan	Tessa Romero	PT Raise	Overweight	$33→$34
Nov 7, 2025	RBC Capital	Leonid Timashev	PT Raise	Outperform	$49→$50
Nov 7, 2025	Wedbush	Laura Chico	PT Cut	Outperform	$35→$32
Sep 25, 2025	Goldman Sachs	Paul Choi	Initiate	Neutral	$20
Aug 19, 2025	JP Morgan	Tessa Romero	PT Cut	Overweight	$40→$30
Aug 8, 2025	RBC Capital	Leonid Timashev	PT Raise	Outperform	$48→$49

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36

Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and raises the price target from $32 to $36.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55

Evercore ISI Group analyst Cory Kasimov maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $45 to $55.

Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Edgewise Therapeutics with Outperform Rating, Announces Price Target of $51

Oppenheimer analyst Mazahir Alimohamed initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform rating and announces Price Target of $51.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Edgewise Therapeutics, Raises Price Target to $51

Guggenheim analyst Debjit Chattopadhyay maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $41 to $51.

Benzinga Newsdesk

Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday

Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax target increased, Sezzle target up, Biogen target raised, Progressive target cut.

Avi Kapoor

PRO
RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $59

RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $48 to $59.

Benzinga Newsdesk

Edgewise Therapeutics Inc

Edgewise Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36

PRO
Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55

PRO
Oppenheimer Initiates Coverage On Edgewise Therapeutics with Outperform Rating, Announces Price Target of $51

PRO
Guggenheim Maintains Buy on Edgewise Therapeutics, Raises Price Target to $51

Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday

PRO
RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $59

People Also Watch

People Also Watch

Benzinga

Benzinga

Edgewise Therapeutics Inc

Edgewise Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGoldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36

PROEvercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55

PROOppenheimer Initiates Coverage On Edgewise Therapeutics with Outperform Rating, Announces Price Target of $51

PROGuggenheim Maintains Buy on Edgewise Therapeutics, Raises Price Target to $51

Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday

PRORBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $59

People Also Watch

People Also Watch

PRO
Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36

PRO
Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55

PRO
Oppenheimer Initiates Coverage On Edgewise Therapeutics with Outperform Rating, Announces Price Target of $51

PRO
Guggenheim Maintains Buy on Edgewise Therapeutics, Raises Price Target to $51

PRO
RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $59